The Indianapolis-based company is planning to reduce by 3% its worldwide R&D workforce, so it can refocus its efforts on certain key research areas.

The company is hoping to get to a volontary exit offering a compensation package to employees who choose to leave the company.

However, there was noo public statement on the decision issued.

According to spokewoman Amy Sousa, Lilly will refocus its  efforts in the areas of Alzheimer’s disease and immunology: 

“We’ll be focusing in on these areas where we need certain areas of expertise, we want to continue to have a great pipeline of potential medicines. We’re focusing on some areas where we think we have some great opportunities.”

This last move is not related to the recent failure of the company’s Alzheimer’s drug Solanezumab. that lead to about 500 field positions cut. 

Lilly has about 40,000 employees worldwide.

Source: Indianapolis Business Journal